Evaluation of MDMA on Startle Response

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-14

Study Completion Date

2020-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants.

The main question it aims to answer is: Does MDMA impact participant's performance on a startle test?

Researchers will compare healthy volunteers who have taken MDMA to those who have taken placebo.

Participants will first undergo a 1-hour startle test. The next day, they will be randomized to receive either MDMA or placebo followed by another startle test and vitals signs and blood measurements. Participants will return the next day for a final startle test. Their sleep will be tracked by a Fitbit device.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

NCT01404754

Psychological Effects of Study Drug

COMPLETED PHASE1

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)

NCT04073433

Psychological Effects of Study Drug

WITHDRAWN PHASE1

Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

NCT01458327

Posttraumatic Stress Disorder

COMPLETED PHASE2

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00353938

Posttraumatic Stress Disorder

COMPLETED PHASE2

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610

Posttraumatic Stress Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, blinded, placebo-controlled Phase 1 study that aims to evaluate the impact of 3,4-methylenedioxymethamphetamine (MDMA) on startle response.

This study will enroll healthy participants. At Visit 1, all participants will undergo a 1-hour startle test. Acoustic startle will be measured through assessing eye-blink response from the orbicularis oculi muscles in response to a 106 dB noise, using sensors under the eye. While watching the computer monitor, the participant will also experience several brief blasts of air directed at the throat.

At Visit 2 (24 hours later), participants will be randomized to receive 100 mg of MDMA or inactive placebo, after which they will undergo another startle test. Participants enrolled in the study who agree to do this will have their blood drawn to measure levels of oxytocin, and possibly other hormones or proteins, such as cortisol or brain-derived neurotrophic factor (BDNF). Measuring oxytocin will be blind to condition, and the decision will happen before randomization to either condition. Blood will be drawn before MDMA or placebo administration, and eight times afterwards.The researchers will measure pulse, blood pressure and temperature once before and six times after receiving MDMA or placebo, and study participants will complete a questionnaire about their experience.

At Visit 3, participants will return for a final startle test and recall task. Sleep will be measured via self-report and Fitbit during study participation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Startle Response

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinded, placebo between group; all participants undergo fear conditioning, with half randomized to receive 100 mg MDMA and half receiving inactive placebo

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

100 mg MDMA HCl

Participants receive 100 mg MDMA HCl on their second visit

Group Type EXPERIMENTAL

Midomafetamine

Intervention Type DRUG

Participants will receive 100 mg midomafetamine HCl on their second visit

Acoustic startle

Intervention Type BEHAVIORAL

Startle assessment

Placebo

Participants receive inactive placebo on their second visit

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Participants will receive inactive placebo on their second visit.

Acoustic startle

Intervention Type BEHAVIORAL

Startle assessment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Participants will receive inactive placebo on their second visit.

Intervention Type DRUG

Midomafetamine

Participants will receive 100 mg midomafetamine HCl on their second visit

Intervention Type DRUG

Acoustic startle

Startle assessment

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

inactive placebo lactose 3,4-methylenedioxymethamphetamine MDMA midomafetamine HCl startle test

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persons aged 21 to 55.
* Ability to visually read and understand English language.
* Live within in metro Atlanta area
* Previously used MDMA in a recreational or research setting
* If a person is of childbearing potential (able to bear children), they must have a negative pregnancy test at study entry and prior to the Experimental Session. They must agree to use adequate birth control through 10 days after the last dose of MDMA. Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, abstinence, oral hormones plus a barrier contraception or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). Not of childbearing potential is defined as permanent sterilization, postmenopausal, or male.
* (For sub-study measuring serum oxytocin) Willing to have periodic blood draws

Exclusion Criteria

* Upon review of medical or psychiatric history, have any current or past diagnosis that would be considered a risk to participating in the study.
* Are abusing illegal drugs.
* Current use of any psychoactive medications, including antidepressants, mood stabilizers, sedatives, stimulants, antipsychotics, anxiolytics, or beta-blockers
* Are not able to give adequate informed consent.
* Uncontrolled hypertension, or clinically significant cardiac arrhythmia, as detected by electrocardiogram.
* Currently pregnant or breast-feeding.
* History of acute angle glaucoma.
* Hearing impairment as assessed by audiometer; unable to detect tones below 40 dB in right or left ear.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes